PRESS RELEASE

Published February 23, 2023

 

United States, Nevada, Las Vegas, DelveInsight’s Acute Respiratory Distress Syndrome Market Insight, Epidemiology and Market Forecast – 2032 report provides current treatment practices, emerging drugs, Acute Respiratory Distress Syndrome market share of the individual therapies, current and forecasted Acute Respiratory Distress Syndrome market size from 2019 to 2032 segmented by seven major markets. The report also offers current Acute Respiratory Distress Syndrome therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Respiratory Distress Syndrome market.

Acute Respiratory Distress Syndrome Overview
ARDS is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible. It is a severe lung condition that causes low blood oxygen. People who develop ARDS are usually ill due to another disease or a major injury which leads to fluid build-up inside the tiny air sacs of the lungs, and surfactant breakdown.
The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.
Usually, the first symptom of ARDS is shortness of breath, cough, and fever. Other signs and symptoms of ARDS are low blood oxygen, rapid breathing, clicking, bubbling, or rattling sounds in the lungs when breathing.

Acute Respiratory Distress Syndrome Epidemiological Insights
According to Delveinsight’s estimates, among the 7MM, the United States has the highest number of ARDS incident cases with approximately 630,500 cases in 2021.

Acute Respiratory Distress Syndrome Treatment Market
Despite decades of research, treatment options for ARDS are restricted. Supportive care with mechanical ventilation remains the mainstay of management. There are relatively few treatments available for ARDS.
Other treatment options, to which the patients with ARDS are generally subjected include supplemental oxygen, prone positioning, use of paralytics, fluid management, and a technique called positive end-expiratory pressure (PEEP) to help push the fluid out of air sacs. These are combined with continuing treatment of the original illness or injury. Because people with ARDS are less able to fight lung infections, they may develop bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also, supportive treatment, such as intravenous fluid or food, may be needed.

Promising Therapies in the Acute Respiratory Distress Syndrome Pipeline
• EB05
• Alteplase (Actilyse)
• BIO-11006
• ExoFlo (DB-001)
• And others

Discover more about Acute Respiratory Distress Syndrome therapies in the pipeline @ Acute Respiratory Distress Syndrome Drugs

Leading Companies Working in the Acute Respiratory Distress Syndrome Market
• Edesa Biotech
• Boehringer Ingelheim/Genentech
• BioMarck Pharmaceuticals
• Direct Biologics
• And others

To understand key companies related to the Acute Respiratory Distress Syndrome Market, get a snapshot of the Acute Respiratory Distress Syndrome Regulatory and Patent Analysis.

Scope of the Acute Respiratory Distress Syndrome Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Acute Respiratory Distress Syndrome Companies: Edesa Biotech, Boehringer Ingelheim/Genentech, BioMarck Pharmaceuticals, Direct Biologics, and others
Key Acute Respiratory Distress Syndrome Pipeline Therapies: EB05, Alteplase (Actilyse), BIO-11006, ExoFlo (DB-001), and others
Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and emerging therapies
Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Acute Respiratory Distress Syndrome Market Access and Reimbursement

Table of Contents
1. Acute Respiratory Distress Syndrome Market Key Insights
2. Acute Respiratory Distress Syndrome Market Report Introduction
3. Acute Respiratory Distress Syndrome Market Overview at a Glance
4. Acute Respiratory Distress Syndrome Market Executive Summary
5. Disease Background and Overview
6. Acute Respiratory Distress Syndrome Treatment and Management
7. Acute Respiratory Distress Syndrome Epidemiology and Patient Population
8. Patient Journey
9. Acute Respiratory Distress Syndrome Emerging Drugs
10. 7MM Acute Respiratory Distress Syndrome Market Analysis
11. Acute Respiratory Distress Syndrome Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Acute Respiratory Distress Syndrome Market Drivers
15. Acute Respiratory Distress Syndrome Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports by DelveInsight:
• Asthma Diagnostic Devices Market
• Chronic Obstructive Pulmonary Disease Treatment Devices Market
• Airway Management Devices Market
• Cough Assist Devices Market
• Pulse Oximeters Market
• Hemodialysis Catheter Devices Market
• Chronic Spontaneous Urticaria Market
• Gender Dysphoria Market
• Germany Healthcare Outlook
• Biopsy Devices Pipeline Insight
• Bacterial Conjunctivitis Market
• Infliximab Biosimilar Insight
• Eosinophilic Asthma Market
• Cushing Syndrome Market
• Functional Dyspepsia Market
• Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Kritika Rehani
[email protected]
+1(919)321-6187

 

Source link